Among them, Ozempic and Mounjaro belong to the GLP-1 class of drugs, a new generation of drugs recently approved by FDA to treat T2D, and have been praised for their weight-loss benefits. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.